Biogen Past Earnings Performance

Past criteria checks 0/6

Biogen's earnings have been declining at an average annual rate of -30.2%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 9.8% per year. Biogen's return on equity is 7.3%, and it has net margins of 12%.

Key information

-30.2%

Earnings growth rate

-23.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-9.8%
Return on equity7.3%
Net Margin12.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Recent updates

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28
Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Revenue & Expenses Breakdown

How Biogen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:BIIB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 249,6721,1592,4892,212
31 Mar 249,6631,1672,4762,333
31 Dec 239,8361,1612,5022,458
30 Sep 239,9931,4622,5372,490
30 Jun 239,9722,6652,3432,303
31 Mar 2310,1053,1312,3792,248
31 Dec 2210,1733,0472,4092,229
30 Sep 2210,3632,8652,5702,325
30 Jun 2210,6342,0592,6612,478
31 Mar 2210,8201,4502,7262,535
31 Dec 2110,9821,5562,6802,497
30 Sep 2111,1011,5462,7003,522
30 Jun 2111,6981,9182,6193,960
31 Mar 2112,6043,0122,5364,023
31 Dec 2013,4454,0012,5163,985
30 Sep 2014,2635,0822,3702,949
30 Jun 2014,4875,9272,3512,348
31 Mar 2014,4225,8792,3652,178
31 Dec 1914,3785,8892,3592,273
30 Sep 1914,2335,3962,2852,193
30 Jun 1914,0725,2942,2292,160
31 Mar 1913,8124,6672,1762,664
31 Dec 1813,4534,4312,1092,597
30 Sep 1813,2343,1872,0702,573
30 Jun 1812,8722,9682,0072,512
31 Mar 1812,5942,9641,9212,327
31 Dec 1712,2742,5391,9362,254
30 Sep 1711,8393,4861,8592,200
30 Jun 1711,7173,2931,8872,283
31 Mar 1711,5333,4801,9491,959
31 Dec 1611,4493,7031,9501,973
30 Sep 1611,4163,8852,0351,981
30 Jun 1611,2383,8182,0511,972
31 Mar 1610,9363,6952,0501,990
31 Dec 1510,7643,5472,1132,013
30 Sep 1510,5653,5992,1041,971
30 Jun 1510,2993,4902,1961,869
31 Mar 1510,1283,2772,2811,825
31 Dec 149,7032,9352,2321,893
30 Sep 149,0282,5092,1541,816
30 Jun 148,3452,1391,9901,808
31 Mar 147,6471,9161,8441,689
31 Dec 136,9321,8621,7121,444
30 Sep 136,3841,6971,5651,367

Quality Earnings: BIIB has a large one-off loss of $679.4M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: BIIB's current net profit margins (12%) are lower than last year (26.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIIB's earnings have declined by 30.2% per year over the past 5 years.

Accelerating Growth: BIIB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIIB had negative earnings growth (-56.5%) over the past year, making it difficult to compare to the Biotechs industry average (0.5%).


Return on Equity

High ROE: BIIB's Return on Equity (7.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies